Literature DB >> 6600967

Suppression of lymphocyte activation by plasma lipoproteins.

M Macy, Y Okano, A D Cardin, E M Avila, J A Harmony.   

Abstract

Activation of T-lymphocytes in vitro by the polyclonal mitogen phytohemagglutinin is inhibited by plasma lipoproteins with hydrated densities of less than 1.063 g/ml and which contain the apolipoproteins B (apoB) of hepatic (apoB100) and intestinal (apoB48) origin and apolipoprotein E (apoE). Lipids are not required for suppression of lymphocyte activation. Purified apoE, apoB48, and apoB100 inhibit phytohemagglutinin-induced phospholipid turnover and DNA synthesis. These apolipoproteins share a common role. All are involved with the transport of cholesterol in the aqueous channels of the body, the lymph and blood. However, the absence of a lipid requirement for suppression indicates that the suppressive mechanism is independent of the low-density-lipoprotein receptor pathway, the major pathway through which cells obtain extracellular cholesterol. The suppressive potency of lipoproteins and apolipoproteins in the proliferative phase of polyclonal lymphocyte activation is determined by the ratio of T-lymphocytes to accessory cells (adherent monocytes). Suppression is greatest when the number of monocytes per culture is low and least when the T-cell:adherent cell ratio is about 1:1. Preincubation of lipoproteins directly with adherent cells reduces the ability of the lipoproteins to inhibit lymphocyte proliferation, suggesting that the adherent cels chemically alter the lipoproteins. The physiological importance of the plasma lipoproteins in regulating the immune response of the host will therefore depend on the lymphocyte:monocyte ratio and on the concentration of suppressive lipoproteins in the lymph nodes and spleen.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6600967

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

Review 1.  The role of apolipoprotein E in Guillain-Barré syndrome and experimental autoimmune neuritis.

Authors:  Hong-liang Zhang; Jiang Wu; Jie Zhu
Journal:  J Biomed Biotechnol       Date:  2010-02-16

Review 2.  The fat-fed apolipoprotein E knockout mouse brachiocephalic artery in the study of atherosclerotic plaque rupture.

Authors:  Andrew R Bond; Christopher L Jackson
Journal:  J Biomed Biotechnol       Date:  2010-11-07

3.  Apolipoprotein E modulates immune activation by acting on the antigen-presenting cell.

Authors:  Charlotta Tenger; Xinghua Zhou
Journal:  Immunology       Date:  2003-07       Impact factor: 7.397

4.  Acute Loss of Apolipoprotein E Triggers an Autoimmune Response That Accelerates Atherosclerosis.

Authors:  Monica Centa; Kajsa E Prokopec; Manasa G Garimella; Katrin Habir; Lisa Hofste; Julian M Stark; Albert Dahdah; Chris A Tibbitt; Konstantinos A Polyzos; Anton Gisterå; Daniel K Johansson; Nobuyo N Maeda; Göran K Hansson; Daniel F J Ketelhuth; Jonathan M Coquet; Christoph J Binder; Mikael C I Karlsson; Stephen Malin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-08       Impact factor: 8.311

5.  APOE genotype-specific differences in the innate immune response.

Authors:  Michael P Vitek; Candice M Brown; Carol A Colton
Journal:  Neurobiol Aging       Date:  2007-12-21       Impact factor: 4.673

6.  Apolipoprotein E Promotes Immune Suppression in Pancreatic Cancer through NF-κB-Mediated Production of CXCL1.

Authors:  Samantha B Kemp; Eileen S Carpenter; Nina G Steele; Katelyn L Donahue; Zeribe C Nwosu; Amanda Pacheco; Ashley Velez-Delgado; Rosa E Menjivar; Fatima Lima; Stephanie The; Carlos E Espinoza; Kristee Brown; Daniel Long; Costas A Lyssiotis; Arvind Rao; Yaqing Zhang; Marina Pasca di Magliano; Howard C Crawford
Journal:  Cancer Res       Date:  2021-05-28       Impact factor: 13.312

Review 7.  Insights into T-cell dysfunction in Alzheimer's disease.

Authors:  Linbin Dai; Yong Shen
Journal:  Aging Cell       Date:  2021-11-01       Impact factor: 9.304

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.